{"id":2339,"date":"2025-10-13T10:53:54","date_gmt":"2025-10-13T17:53:54","guid":{"rendered":"https:\/\/www.spatomics.com\/?p=2339"},"modified":"2025-10-13T11:03:48","modified_gmt":"2025-10-13T18:03:48","slug":"nih-and-spatomics-co-author-study-in-cell-reports-medicine","status":"publish","type":"post","link":"https:\/\/www.spatomics.com\/zh\/2025\/10\/13\/nih-and-spatomics-co-author-study-in-cell-reports-medicine\/","title":{"rendered":"NIH and Spatomics Co-author Study in Cell Reports Medicine"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"2339\" class=\"elementor elementor-2339\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c216ede e-flex e-con-boxed e-con e-parent\" data-id=\"c216ede\" data-element_type=\"container\" data-settings=\"{&quot;content_width&quot;:&quot;boxed&quot;}\" data-core-v316-plus=\"true\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e8a4389 elementor-widget elementor-widget-text-editor\" data-id=\"e8a4389\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t<style>\/*! elementor - v3.17.0 - 08-11-2023 *\/\n.elementor-widget-text-editor.elementor-drop-cap-view-stacked .elementor-drop-cap{background-color:#69727d;color:#fff}.elementor-widget-text-editor.elementor-drop-cap-view-framed .elementor-drop-cap{color:#69727d;border:3px solid;background-color:transparent}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap{margin-top:8px}.elementor-widget-text-editor:not(.elementor-drop-cap-view-default) .elementor-drop-cap-letter{width:1em;height:1em}.elementor-widget-text-editor .elementor-drop-cap{float:left;text-align:center;line-height:1;font-size:50px}.elementor-widget-text-editor .elementor-drop-cap-letter{display:inline-block}<\/style>\t\t\t\t<p><strong>Guilford, CT. \u2013<\/strong><strong> October 13, 2025. AbTCR T Cells Targeting GPC2 Show Potent Efficacy Against Low-Antigen Neuroblastoma.<\/strong><\/p><p data-start=\"367\" data-end=\"762\">A recent study published in <em data-start=\"395\" data-end=\"418\">Cell Reports Medicine<\/em> highlights a collaborative effort between the National Institutes of Health (NIH), Eureka Therapeutics, and Spatomics LLC. The research demonstrates that antibody-\u03b3\u03b4 T cell receptors (AbTCRs) targeting the oncofetal antigen GPC2 can induce potent regression of neuroblastoma, even in tumors with very low antigen density.<\/p><p data-start=\"764\" data-end=\"1117\">The team engineered AbTCR T cells using CT3 or humanized CT3 (hCT3) antibodies and found that these cells exhibited stronger cytotoxic activity and greater CD8\u207a T-cell infiltration than conventional CAR-T cells. These findings suggest AbTCR-based therapy as a promising approach for solid tumors that typically resist standard immunotherapies.<\/p><p data-start=\"1188\" data-end=\"1633\"><strong data-start=\"1188\" data-end=\"1241\">Spatomics\u2019 CFP\u2122 Multiplex Protein Detection Assay<\/strong> played a key role in the study by enabling high-resolution spatial profiling of immune cell infiltration and activation in tumor tissues. Using CFP\u2122 cleavable tyramide signal amplification, researchers were able to visualize and quantify T-cell subsets such as <strong data-start=\"1503\" data-end=\"1531\">CD45RA\u207a, CD27\u207a, and CD8\u207a<\/strong> within the tumor microenvironment, providing mechanistic insights into AbTCR function and efficacy.<\/p><p data-start=\"1635\" data-end=\"1670\"><strong>Advantages of CFP\u2122 Technology<\/strong><\/p><ul><li data-start=\"1673\" data-end=\"1762\"><strong data-start=\"1673\" data-end=\"1707\">High sensitivity and precision<\/strong> for visualizing immune cell dynamics in FFPE tissues<\/li><li data-start=\"1765\" data-end=\"1842\"><strong data-start=\"1765\" data-end=\"1804\">Tyramide-based signal amplification<\/strong> for detecting low-abundance targets<\/li><li data-start=\"1845\" data-end=\"1949\"><strong data-start=\"1845\" data-end=\"1876\">Gentle fluorophore cleavage<\/strong> for multi-round, iterative staining without damaging tissue morphology<\/li><li data-start=\"1952\" data-end=\"2055\"><strong data-start=\"1952\" data-end=\"1969\">Compatibility<\/strong> with standard automated IHC stainers such as Leica BOND Rx and Biocare Oncore Pro X<\/li><\/ul><p data-start=\"2057\" data-end=\"2233\">Together, these results underscore how <strong data-start=\"2096\" data-end=\"2123\">Spatomics CFP\u2122 reagents<\/strong> empower spatial immune profiling and accelerate next-generation cell therapy and tumor immunology research.<\/p><p data-start=\"2235\" data-end=\"2450\"><img decoding=\"async\" class=\"emoji\" role=\"img\" draggable=\"false\" src=\"https:\/\/s.w.org\/images\/core\/emoji\/16.0.1\/svg\/1f4d6.svg\" alt=\"\ud83d\udcd6\" \/> <em data-start=\"2238\" data-end=\"2376\">Quan et al., \u201cAntibody-\u03b3\u03b4 T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density,\u201d Cell Reports Medicine (2025).<\/em><br data-start=\"2376\" data-end=\"2379\" \/><a class=\"decorated-link\" href=\"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102378\" target=\"_new\" rel=\"noopener\" data-start=\"2379\" data-end=\"2448\">Read the full article \u2192<\/a><\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Guilford, CT. \u2013 October 13, 2025. AbTCR T Cells Targeting GPC2 Show Potent Efficacy Against Low-Antigen Neuroblastoma. A recent study &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/www.spatomics.com\/zh\/2025\/10\/13\/nih-and-spatomics-co-author-study-in-cell-reports-medicine\/\"> <span class=\"screen-reader-text\">NIH and Spatomics Co-author Study in Cell Reports Medicine<\/span> Read More \u00bb<\/a><\/p>","protected":false},"author":1,"featured_media":2344,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[16],"class_list":["post-2339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-news"],"_links":{"self":[{"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/posts\/2339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/comments?post=2339"}],"version-history":[{"count":7,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/posts\/2339\/revisions"}],"predecessor-version":[{"id":2347,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/posts\/2339\/revisions\/2347"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/media\/2344"}],"wp:attachment":[{"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/media?parent=2339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/categories?post=2339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.spatomics.com\/zh\/wp-json\/wp\/v2\/tags?post=2339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}